1
|
Feldman KM, Coughlin A, Feliciano J, Stoffels G, Wang KZ, Strauss TS, Grubman O, Al-Ibraheemi Z, Cole D, Ashmead G, Hussain F, Shchur SS, Lee D, Brustman L. Neonatal Birth Weight With Daily Compared With Every-Other-Day Glucose Monitoring in Gestational Diabetes Mellitus: A Randomized Controlled Trial. Obstet Gynecol 2024:00006250-990000000-01021. [PMID: 38330409 DOI: 10.1097/aog.0000000000005528] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 10/02/2023] [Accepted: 12/21/2023] [Indexed: 02/10/2024]
Abstract
OBJECTIVE To assess whether universal use of every-other-day glucose monitoring in patients with gestational diabetes mellitus (GDM) resulted in similar birth weights and medication use and was preferred by the patient compared with traditional daily glucose monitoring. METHODS This was a noninferiority randomized controlled trial conducted at a single New York City hospital between April 2021 and May 2022. Patients with singleton pregnancies who were diagnosed with GDM after 20 weeks of gestation and had a minimum of 7 days of previous daily blood glucose testing were randomly assigned to test blood glucose values daily or every other day. The primary outcome was neonatal birth weight. We calculated a total sample size of 196 participants needed for noninferiority to be tested, assuming the mean birth weight in the every-other-day group, compared with the daily group, was no higher than the predefined noninferiority margin of 200 g (80% power and one-sided alpha of 0.05). Postrandomization characteristics, including blood glucose values and medication initiation and timing, were recorded. Satisfaction with treatment group was assessed using the validated Oxford Maternity Diabetes Treatment Satisfaction Questionnaire. RESULTS A total of 197 patients were randomized: 98 in the daily group and 99 in the every-other-day group. Baseline characteristics were similar between groups. The mean neonatal birth weight was similar between groups (mean±SD 3,090±418 g among newborns in the daily group compared with 3,181±482 g among newborns in the every-other-day group). For the primary outcome, the every-other-day group was found to be noninferior to the daily group with an upper confidence limit for the mean difference in mean birth weight of 197 g, which was below the noninferiority margin of 200 g (P=.046). Postrandomization, there were no significant differences in the number of patients who required medication, the gestational age at which medication was started, or the type of medication used. Average fasting and postprandial glucose values were similar between groups. There was an increase in adherence to treatment group in those randomized to every-other-day blood sugars, but no difference in patient satisfaction. CONCLUSION In patients with GDM, testing blood glucose values every other day was as effective as testing daily, without apparent effects on birth weight, medication initiation, or glucose control. Reduced frequency of blood glucose monitoring might help decrease the emotional, physical, and financial burden experienced by patients with GDM. CLINICAL TRIAL REGISTRATION ClinicalTrials.gov, NCT04857073.
Collapse
Affiliation(s)
- Kristina Martimucci Feldman
- Division of Maternal-Fetal Medicine, Obstetrics, Gynecology and Reproductive Medicine, Mount Sinai West, Obstetrics, Gynecology and Reproductive Medicine, Mount Sinai West, and the Department of Population Health Science and Policy, Icahn School of Medicine at Mount Sinai, New York, New York
| | | | | | | | | | | | | | | | | | | | | | | | | | | |
Collapse
|
2
|
Hussain FN, Rosenbluth E, Feldman KM, Strauss TS, Schneider E, Schmidt-Beauchat E, Rodriguez-Rivas C, Brustman L, Kushner T. Transient elastography and controlled attenuation parameter to evaluate hepatic steatosis and liver stiffness in postpartum patients. J Matern Fetal Neonatal Med 2023; 36:2190838. [PMID: 36935368 DOI: 10.1080/14767058.2023.2190838] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 03/21/2023]
Abstract
INTRODUCTION Nonalcoholic fatty liver disease (NAFLD) affects 30% of adults in the United States. Transient elastography (TE) (Fibroscan, Echosens, Paris, France) with controlled attenuation parameter (CAP) is a noninvasive way to evaluate liver steatosis and liver stiffness. The primary objective of this study was to assess prevalence of elevated liver stiffness and steatosis immediately postpartum. Furthermore, we sought to evaluate whether there were differences in rates of metabolic disorders of pregnancy (gestational diabetes mellitus (GDM), gestational hypertension, and preeclampsia) and pre-pregnancy conditions (type 2 diabetes mellitus (DM), chronic hypertension, and obesity) in those with elevated postpartum liver steatosis/liver stiffness. METHODS IRB approved prospective cross-sectional study in which TE and liver function tests were performed 1-2 days postpartum. CAP ≥300 dB/m was classified as significant steatosis. Increased liver stiffness was defined as ≥7 kPa. Prevalence was determined by proportion of individuals undergoing TE/CAP who met criteria. Chi-square analysis was used to compare differences between groups. RESULTS Eighty-nine patients were included: 20 (22%) had GDM, 13 (15%) had gestational hypertension, and 15 (17%) had preeclampsia. Women with kPa ≥7 were more likely to have ALT ≥25, type 2 diabetes, and preeclampsia (p < .05). Pre-gravid BMI, BMI at delivery, and GDM were not associated with increased kPa. Pregravid BMI ≥25 and chronic hypertension were associated with CAP ≥ 300 dB/m (p < .05). GDM, preeclampsia, and gestational hypertension were not associated with CAP ≥300 dB/m. CONCLUSIONS Patients with preeclampsia, type 2 diabetes, and elevated ALT were more likely to have elevated postpartum liver stiffness. Pregravid BMI ≥25 and ≥30 were associated with increased liver steatosis, although did not impact liver stiffness. GDM was not associated with increased liver stiffness or steatosis. Consideration should be made for screening pregnant patients with preeclampsia, type 2 DM and overweight or obese BMI for liver disease in the postpartum period with potential for lifestyle intervention.
Collapse
Affiliation(s)
- Farrah Naz Hussain
- Department of Obstetrics, Gynecology and Reproductive Science, Division of Maternal Fetal Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Emma Rosenbluth
- Department of Medicine, Northwestern University Feinberg School of Medicine, Chicago, IL, USA
| | - Kristina Martimucci Feldman
- Department of Obstetrics, Gynecology and Reproductive Science, Division of Maternal Fetal Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Tirtza Spiegel Strauss
- Department of Obstetrics, Gynecology and Reproductive Science, Division of Maternal Fetal Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Emily Schneider
- Department of Obstetrics, Gynecology and Reproductive Science, Division of Maternal Fetal Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Emily Schmidt-Beauchat
- Department of Obstetrics, Gynecology and Reproductive Science, Division of Maternal Fetal Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Clara Rodriguez-Rivas
- Division of Liver Diseases, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Lois Brustman
- Department of Obstetrics, Gynecology and Reproductive Science, Division of Maternal Fetal Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Tatyana Kushner
- Department of Obstetrics, Gynecology and Reproductive Science, Division of Maternal Fetal Medicine, Icahn School of Medicine at Mount Sinai, New York, NY, USA
- Division of Liver Diseases, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| |
Collapse
|
3
|
Hussain FN, Raymond S, Feldman K, Scarpelli Shchur S, Spiegel Strauss T, Al-Ibraheemi Z, Brustman L. Comparison of an intermittently scanned (flash) continuous glucose monitoring system to standard self-monitoring of capillary blood glucose in gestational diabetes mellitus. Am J Perinatol 2023. [PMID: 36918164 DOI: 10.1055/a-2053-7650] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Track Full Text] [Journal Information] [Submit a Manuscript] [Subscribe] [Scholar Register] [Indexed: 03/16/2023]
Abstract
Objective Gestational diabetes mellitus (GDM) requires close surveillance of blood glucose to prevent perinatal morbidity. Self-monitoring of capillary blood glucose (BGM) comes with considerable psychosocial burden. Intermittently scanned CGM (isCGM) devices are discreet and could considerably impact the lifestyle of the patient. They are designed to replace BGM testing in nonpregnant patients. Data on this technology in pregnancy is scant. The aim of this study was to assess concordance of BGM with isCGM in GDM. Methods IRB approved prospective single arm study evaluating agreement of isCGM (Freestyle Libre 14 day system) compared to BGM when determining glucose levels fasting and 2 hours postprandial for 14 days. This was documented as percentage of results within Zone A (clinically accurate measurements with no effect on clinical action) or Zone B (values that deviate from reference by >20% but would lead to benign/no treatment) of the Parkes Error Grid (developed for non-pregnant patients with diabetes). Per International Organization for Standardization (ISO) criteria, agreement was defined as >95% within Zone A or B. Analytical agreement was evaluated using mean and median absolute relative difference (ARD), mean and median absolute difference (AD). Results There were 1604 pairs of BGM/isCGM observations for 41 patients. Mean glucose values were 102.0 (SD 20.5) mg/dL and 89.4 (SD 20.1) mg/dL for BGM and isCGM, respectively. Mean and median AD were 15.9 and 13.0 mg/dL, respectively. Mean and median ARD were 15.9% and 12.5%, respectively. Zones A and B contained 76.9% and 22.9% of values, respectively, in the Parkes Error Grid, for a total of 99.8%. Conclusions BGM and isCGM demonstrate clinical agreement. However, glucose values with isCGM trended lower, with greater mean and median ARD than prior studies. Given the strict glycemic control required during pregnancy, physicians should be aware of these differences and their possible clinical implications.
Collapse
Affiliation(s)
| | - Samantha Raymond
- Icahn School of Medicine at Mount Sinai, New York, United States
| | - Kristina Feldman
- Obstetrics and Gynecology, Icahn School of Medicine at Mount Sinai, New York, United States
| | | | - Tirtza Spiegel Strauss
- Obstetrics and Gynecology, Icahn School of Medicine at Mount Sinai, New York, United States
| | | | - Lois Brustman
- Maternal Fetal Medicine, Obstetrics and Gynecology, Mount Sinai West, New York, United States
| |
Collapse
|
4
|
Strauss TS, Boniferro E, Brockhoff E, Johnson A, Schneider E, Grubman O, Cole D, Hussain F, Ashmead G, Al-Ibraheemi Z, Brustman L. Opening Pandora's box: abnormal genetic carrier screening and need for lifetime follow-up. Am J Obstet Gynecol MFM 2023; 5:100820. [PMID: 36455867 DOI: 10.1016/j.ajogmf.2022.100820] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [MESH Headings] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Received: 11/13/2022] [Accepted: 11/22/2022] [Indexed: 11/29/2022]
Abstract
OBJECTIVE Expanded carrier screening (ECS) is rising in popularity because of its application in a diverse population, its decreasing cost, and efficiency.1 However, it has traditionally been used to assess fetal risk. The next generation sequencing ECS panel offered at our academic medical center consists of 283 genes associated with hereditary disorders. Of those, 20 (7.1%) are autosomal recessive conditions, notable for variable expression of the clinical phenotype in heterozygous carriers, which may increase maternal risk for malignancy, bleeding, cardiovascular, or rheumatologic disease. Another 21 (7.4%) are X-linked conditions. We aimed to evaluate the prevalence of variants that have a potential for maternal phenotypic expression and whether identification of specific variants prompted patients to pursue further care in our health system, namely comprehensive genetic counseling and further healthcare consults when recommended. STUDY DESIGN An institutional review board-approved descriptive retrospective cohort study was performed in a New York City academic medical center at which reproductive aged women were offered universal ECS from 2018 to 2021 by their provider, inclusive of obstetrician-gynecologists, maternal-fetal medicine physicians, and genetic counselors. Pretest counseling was performed by the ordering provider. Patients found to carry mutations with the potential for maternal phenotypic expression were contacted by genetic counselors regarding their clinical risks. In addition, patients who were carriers for factor XI deficiency, Bernard Soulier syndrome, ataxia telangectesia, fumarase deficiency, Nijmegen breakage syndrome, Duchenne muscular dystrophy, and familial hypercholesterolemia were advised to seek specialized healthcare pertaining to their clinical risk. The genetic counseling summary was placed in the electronic medical records (EMRs) so that the primary provider could view the findings. Through our EMRs, we evaluated the rates of healthcare uptake among these patients for at least 1 year after delivery. RESULTS In total, 168 of 1184 (14.2%) patients were identified as carriers of mutations with a potential for maternal phenotypic expression. Of these, 156 (93%) were pregnant and 12 (7%) were preconception. Of those patients, 143 (85%) were carriers of autosomal recessive traits (Figure 1), whereas 22 of 168 (13%) patients were carriers of X-linked conditions (Figure 2) and 3 of 168 (2%) patients carried both autosomal recessive traits and X-linked conditions. Of these carriers, 132 of 168 (78.6%) patients underwent genetic counseling. The most common heterozygous mutations were sickle cell trait (25.6%), thalassemia (alpha and/or beta) trait (14.2%), factor XI deficiency (4.7%), dystrophic epidermolysis bullosa (4.2%), and Alport syndrome (4.1%). Two patients were diagnosed as homozygous carriers of nonclassical congenital adrenal hyperplasia. During the study period, 23 of 168 (13.6%) patients were heterozygous for specific pathogenic variants (inclusive of factor XI, Bernard Soulier syndrome, ataxia telangectesia, fumarase deficiency, Nijmegen breakage syndrome, Duchenne muscular dystrophy, and familial hypercholesterolemia) and were advised to seek specialized healthcare pertaining to these findings. Of these, 20 (87.0%) received genetic counseling with standardized recommendations, however, only 4 of 23 (17%) patients pursued the recommended referrals during our study period. CONCLUSION This study described the follow-up rates among patients identified as carriers of conditions with the potential for maternal phenotypic expression using ECS. We observed that 14.2% of patients who underwent ECS were identified as carriers of genetic mutations with the potential for maternal phenotypic expression, and of the 23 who were recommended specific care because a pathogenic variant was identified, only 17.4% of patients followed the recommendations. We believe that as ECS implementation becomes widespread, more maternal carriers with clinical risk to themselves will be identified. Therefore, as we open this Pandora's box, the burden of counseling and follow-up must be addressed.
Collapse
Affiliation(s)
- Tirtza Spiegel Strauss
- Division of Maternal Fetal Medicine, Mount Sinai West, Icahn School of Medicine at Mount Sinai, 1000 10th Ave., New York, NY 10019.
| | - Emily Boniferro
- Division of Maternal Fetal Medicine, Mount Sinai West, Icahn School of Medicine at Mount Sinai, 1000 10th Ave., New York, NY 10019
| | - Erika Brockhoff
- Division of Maternal Fetal Medicine, Mount Sinai West, Icahn School of Medicine at Mount Sinai, 1000 10th Ave., New York, NY 10019
| | - Anna Johnson
- Division of Maternal Fetal Medicine, Mount Sinai West, Icahn School of Medicine at Mount Sinai, 1000 10th Ave., New York, NY 10019
| | - Emily Schneider
- Division of Maternal Fetal Medicine, Mount Sinai West, Icahn School of Medicine at Mount Sinai, 1000 10th Ave., New York, NY 10019
| | - Olivia Grubman
- Division of Maternal Fetal Medicine, Mount Sinai West, Icahn School of Medicine at Mount Sinai, 1000 10th Ave., New York, NY 10019
| | - David Cole
- Division of Maternal Fetal Medicine, Mount Sinai West, Icahn School of Medicine at Mount Sinai, 1000 10th Ave., New York, NY 10019
| | - Farrah Hussain
- Division of Maternal Fetal Medicine, Mount Sinai West, Icahn School of Medicine at Mount Sinai, 1000 10th Ave., New York, NY 10019
| | - Graham Ashmead
- Division of Maternal Fetal Medicine, Mount Sinai West, Icahn School of Medicine at Mount Sinai, 1000 10th Ave., New York, NY 10019
| | - Zainab Al-Ibraheemi
- Division of Maternal Fetal Medicine, Mount Sinai West, Icahn School of Medicine at Mount Sinai, 1000 10th Ave., New York, NY 10019
| | - Lois Brustman
- Division of Maternal Fetal Medicine, Mount Sinai West, Icahn School of Medicine at Mount Sinai, 1000 10th Ave., New York, NY 10019
| |
Collapse
|
5
|
Feldman KM, Coughlin A, Feliciano J, Stoffels G, Strauss TS, Grubman O, Al-Ibraheemi Z, Cole D, Ashmead G, Hussain FN, Scarpelli-Shchur S, Brustman L. Daily versus every-other day glucose monitoring in gestational diabetes mellitus: a randomized controlled trial. Am J Obstet Gynecol 2023. [DOI: 10.1016/j.ajog.2022.11.098] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
|
6
|
Strauss TS, Markovic ES, Scarpelli-Shchur S, Grubman O, Owens T, Stoffels G, Cole D, Ashmead G, Hussain FN, Al-Ibraheemi Z, Brustman L. What is the implication of a HbBA1C ≥5.7% in patients with gestational diabetes? Am J Obstet Gynecol 2023. [DOI: 10.1016/j.ajog.2022.11.702] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 01/09/2023]
|
7
|
Strauss TS, Dutton A, Cary C, Boniferro E, Stoffels G, Feldman K, Hussain F, Ashmead G, Al-Ibraheemi Z, Brustman L. The role of the first trimester screen in the face of normal cell free DNA. J Matern Fetal Neonatal Med 2022; 35:9907-9912. [PMID: 35603424 DOI: 10.1080/14767058.2022.2075695] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Affiliation(s)] [Abstract] [Key Words] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 10/18/2022]
Abstract
OBJECTIVE There is no consensus for the method of aneuploidy screening in pregnancy. Cell free DNA (cfDNA) is the most sensitive screen for trisomies 21, 13, and 18, however the first trimester screen (FTS) is a marker for other adverse outcomes, such as structural anomalies, growth restriction, and preeclampsia. In 2019, we offered FTS (nuchal translucency (NT) and analytes) with or without cfDNA. The purpose of this study was to assess clinical relevance of abnormal FTS in women with normal cfDNA. METHODS We retrospectively reviewed women undergoing screening in our Fetal Evaluation Unit in 2019. Women included had normal cfDNA and abnormal FTS; consisting of NT >95%, PAPP-A < 0.4 MoM, beta-HCG >2.5 MoM, or overall increased risk of trisomies. RESULTS 195 patients had abnormal FTS and normal cfDNA. 41 (21%) had adverse maternal outcomes including hypertension, abnormal placentation, and placental abruption. 34 (17%) had adverse fetal outcomes including growth restriction, structural anomalies, fetal demise, polyhydramnios, previable PPROM, necrotizing enterocolitis after a preterm birth, and a balanced translocation. CONCLUSION Abnormal FTS predicts adverse outcomes in 33% of women with normal cfDNA. Our data suggests that offering universal FTS with cfDNA may have clinical benefit.
Collapse
Affiliation(s)
- Tirtza Spiegel Strauss
- Department of Obstetrics and Gynecology, Division of Maternal Fetal Medicine, Mount Sinai West, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Alana Dutton
- Department of Obstetrics and Gynecology, Division of Maternal Fetal Medicine, Mount Sinai West, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Christina Cary
- Department of Obstetrics and Gynecology, Division of Maternal Fetal Medicine, Mount Sinai West, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Emily Boniferro
- Department of Obstetrics and Gynecology, Division of Maternal Fetal Medicine, Mount Sinai West, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Guillaume Stoffels
- Department of Obstetrics and Gynecology, Division of Maternal Fetal Medicine, Mount Sinai West, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Kristina Feldman
- Department of Obstetrics and Gynecology, Division of Maternal Fetal Medicine, Mount Sinai West, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Farrah Hussain
- Department of Obstetrics and Gynecology, Division of Maternal Fetal Medicine, Mount Sinai West, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Graham Ashmead
- Department of Obstetrics and Gynecology, Division of Maternal Fetal Medicine, Mount Sinai West, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Zainab Al-Ibraheemi
- Department of Obstetrics and Gynecology, Division of Maternal Fetal Medicine, Mount Sinai West, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| | - Lois Brustman
- Department of Obstetrics and Gynecology, Division of Maternal Fetal Medicine, Mount Sinai West, Icahn School of Medicine at Mount Sinai, New York, NY, USA
| |
Collapse
|
8
|
Strauss TS, Schneider E, Boniferro E, Johnson A, Brockhoff E, Feldman K, Grubman O, Hussain F, Cole D, Ashmead G, Al-Ibraheemi Z, Brustman L. OP053: Barriers to completion of expanded carrier screening in an inner city population. Genet Med 2022. [DOI: 10.1016/j.gim.2022.01.599] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022] Open
|
9
|
Hussain FN, Feldman KM, Raymond S, Scarpelli-Shchur S, Strauss TS, Al-Ibraheemi Z, Brustman L. Painless and discrete intermittently scanned continuous glucose monitoring in gestational diabetes: as accurate as fingersticks? Am J Obstet Gynecol 2022. [DOI: 10.1016/j.ajog.2021.11.944] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
10
|
Strauss TS, Scarpelli-Shchur S, Feldman KM, Stoffels G, Grubman O, Hussain FN, Cole D, Ashmead G, Al-Ibraheemi Z, Brustman L. Does hemoglobin A1c level predict need for hypoglycemic agents in gestational diabetes? Am J Obstet Gynecol 2022. [DOI: 10.1016/j.ajog.2021.11.216] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/30/2022]
|
11
|
Feldman KM, Robinson A, Scarpelli-Shchur S, Stoffels G, Al-Ibraheemi Z, Strauss TS, Grubman O, Hussain FN, Cole D, Ashmead G, Brustman L. Is glucose paneling a safe alternative to standard diagnostic tests for Gestational Diabetes Mellitus? Am J Obstet Gynecol 2022. [DOI: 10.1016/j.ajog.2021.11.687] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/01/2022]
|
12
|
Feldman KM, Gellman C, Robinson A, Kaplowitz E, Hussain FN, Strauss TS, Al-Ibraheemi Z, Cole D, Brustman L. 556 Resolved but not forgotten: does a diagnosis of resolved placenta previa affect labor and delivery? Am J Obstet Gynecol 2021. [DOI: 10.1016/j.ajog.2020.12.577] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/25/2022]
|